Navigation Links
AMIA advises FDA on clinical decision support
Date:9/14/2011

Washington, DCIn response to the U.S. Food and Drug Administration's (FDA) invitation to participate in a public workshop related to FDA's Draft Guidance on mobile medical applications, AMIAthe association for informatics professionalsadvised the FDA on how it should approach oversight of clinical decision support systems. The critical factor, stated AMIA, in determining the risk classification of different types of software that provide clinical decision support (CDS) is whether the CDS is mediated by a human being or not. The FDA's most rigorous attention, AMIA pointed out, should be given to applications that provide CDS in an automatic and autonomous fashion, and which intervene directly, based on patient care data. AMIA's comments were delivered by Meryl Bloomrosen, Vice President for Public Policy and Government Relations.

AMIA cautioned the FDA about the future blurring of lines between CDS information delivery channels and mechanisms, devices, and applications intended primarily for use by clinicians and other providers, contrasted with those intended for patients, consumers and their care-givers. AMIA also questioned the singling out of "stand-alone" CDS delivered via "mobile medical devices" as being suitable for FDA oversight, more than other kinds of clinical software environments, such as desktop computers.

"AMIA's comments are premised upon practical evidence that the health sector is exploding with an array of clinical information systems for potential use in a broad range of settings," said AMIA President and CEO Edward H. Shortliffe, MD, PhD, FACMI. "A growing volume of research demonstrates that health information technology in many forms and on many kinds of devices can improve the quality and safety of patient care, and promote efficiencies in overall care delivery. In this modern era of ubiquitous electronic data and access, it is important to have regulations that keep pace with cliniciansmany of whom are becoming quite expert at using technology to access pertinent information, and thereby streamlining healthcare delivery and improving overall health."

The Sept. 12-13 workshop fostered discussion between FDA officials and interested stakeholders about the FDA's proposed oversight approach to mobile medical applications. The applications under discussion are those that serve as accessories to other medical devices, that are stand-alone software that provide clinical decision support, and that are for use on smartphones and other mobile computing devices. Prior to the workshop, the FDA had identified a subset of mobile medical applications that might have impact on the performance of currently regulated medical devices, and as such would require FDA oversight.

In its presentation, AMIA focused on several key areas:

  • The need for the FDA to articulate how it characterizes and defines "CDS".
  • The need to coordinate efforts among federal agencies and public- and private-sector research and practice communities.
  • The potential limitations if FDA focuses too narrowly on CDS, and considers CDS on mobile devices as somehow separate from CDS based on other delivery methods or contexts.
  • The importance of addressing rapidly emerging and converging technologies and devices along with new and evolving forms of patient care delivery (such as medical homes and accountable care organizations) and payment methods.


'/>"/>

Contact: Nancy Light
nlight@amia.org
301-657-5903
American Medical Informatics Association
Source:Eurekalert

Related biology news :

1. Overwhelmed by diet tips? Change your environment first, study advises
2. Reports highlight the evolving role of clinical microbiology laboratories
3. New research validates clinical importance of leukemia stem cells
4. Clinical study shows young brains lack the wisdom of their elders
5. Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment
6. Mount Sinai receives $3.4 million for largest study of personalized medicine in the clinical setting
7. New IOF-ISCD review clarifies the use of FRAX in clinical practice
8. New edition of Manual of Clinical Microbiology offers digital access
9. Clinical tests for medicines made from genetically modified plants
10. Omnicare Clinical Research Re-Brands as Theorem Clinical Research
11. NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
(Date:3/15/2016)... ALBANY, New York , March 15, 2016 ... a new market report published by Transparency Market Research "Digital ... Growth, Trends and Forecast 2015 - 2023," the global digital ... at US$ 731.9 Mn in 2014 and is forecast to ... to 2023. Growth of micro, small and medium enterprises (MSMEs) ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... ... 27, 2016 , ... Weeks after hosting a carpal tunnel syndrome workshop with ... surgeon and founder of the Fitzmaurice Hand Institute, has announced the addition of MRI ... state-of-the-art technology and only 1 of about 3 currently available in the United States. ...
(Date:5/27/2016)... ... ... Doctors in Italy, Japan, the UK and the US have reached some surprising ... its link to malignant mesothelioma. Surviving Mesothelioma has just posted the details of their ... , The studies analyzed for the new report included more than 3,447 cancer patients. ...
(Date:5/27/2016)... At present, the Biotech sphere is in a ... volatility is what makes this industry interesting to consider. Here ... (NASDAQ: SNTA ), CTI BioPharma Corp. (NASDAQ: ... and Heat Biologics Inc. (NASDAQ: HTBX ). Sign ... these stocks at: http://www.activewallst.com/register/ ...
(Date:5/26/2016)... New Jersey and READING, ... Indegene ( http://www.indegene.com ), a leading ... to life science, pharmaceutical and healthcare organisations and ... of innovative scientific support throughout the product lifecycle, ... with the launch of IntraScience.      ...
Breaking Biology Technology: